Diagnostic and Prognostic study (DPMS)
Prognostic and Natural History study (PNHS)
Longitudinal Cohort Study (LCS)
EMIF-AD multimodal biomarker discovery study (MBD)
EMIF-AD 90+ study
EMIF-AD PreclinAD study
AETIONOMY PD cohort
EMIF platform EHR resource
Omics data on patient tissue and cellular disease models
Animal data from multi-site experiments
Omics data from iPSC cells, humanised ApoE mouse models
Genetic screens for tau and alpha-synuclein aggregation
Omics data from CSF/plasma from MCI patients
Neuroimaging data from the KCL neuroimaging study
Clinical, biomarker and neuroimaging data from the EPAD LCS study
Neuroimaging datasets from the AMYPAD PNHS and DPMS studies
Clinical, neuroimaging and -omics datasets from EMIF-AD MBD, 90+ and PreClinAD studies
Clinical, neuroimaging and -omics datasets from AETIONOMY PD study
Real-world data from RADAR-AD study of multiple wearable and digital devices
DNA, CSF, plasma, serum and fibroblasts samples from the AETIONOMY PD study
Biosamples from people with AD, MCI, or healthy individuals
CSF samples from the TREM2 variant cohort of KCL
Longitudinal Cohort Study biosamples
Plasma, DNA and CSF from participants of the EMIF-AD Multimodal biomarker discovery study (MBD)
Blood samples, CSF and skin biopsies from participants of the EMIF-AD 90+ study
Blood and CSF from participants of the EMIF-AD PreclinAD study
EQIPD Training Platform
AETIONOMY Knowledge Base
NeuroMMSig server
Data and Knowledge platform from Fraunhofer
Trial Delivery Centre (TDC) network
The EPAD Register
Proof of Concept Trial Platform
EMIF Platform and Catalogue
EQIPD Quality System
Tools and assays for targeting and analysing TREM2 & CD33
Tools for isolating and characterising Tau & a-Synuclein, including aggregation assays
Participant Registry in EPAD (PREPAD) tool
DerIDIOM tool
VElocity for EPAD (VEEPAD) tool
Subject Enrolment in EPAD (SEEPAD) tool
Ethics work on biomarker disclosure
Procedures for trial delivery centre certification, agreement template, etc.
DTA Templates
Stratification Algorithms
Patient engagement protocols
Data Cube
Technology and device guidelines for evaluating ADL
EXAG Advisory Agreement Template
Research Participant Panel
Patient Advisory Board
Protocols for patient engagement
Biology of the BBB and transport mechanisms
Variables in preclinical AD research that influence outcomes
Living systematic review
Function of TREM2, CD33 and related immunomodulatory pathways in AD
Role of the ApoE gene in AD
Mechanism-based pathophysiology of AD and PD
Pre-clinical modelling of protein aggregation in PD and AD
Engagement approaches for different patient groups
Understanding of earliest stages of AD
Value of amyloid imaging in AD diagnosis, prognosis, and potential for treatment monitoring
Risk factors for amyloid pathology, predictors for cognitive decline: clinical biology of AD
Digital biomarkers to evaluate functional decline in AD
Relevant functional outcomes for different stakeholder groups
In vitro and in silico models of the blood-brain barrier
iPSC-derived cell models of ApoE risk alleles
iPSC-based and organotypic cultures, neuronal models and animal models of alpha-synuclein or tau aggregation or propagation
In silico model of neurodegenerative disease mechanisms
AD neuroimaging data risk prediction model
Ontology for describing animal experiments
EPAD Academy